Successful treatment of hepatosplenic candidiasis with a liposomal amphotericin B preparation.
The case of a granulocytopenic patient with acute undifferentiated leukaemia and hepatosplenic candidiasis who was refractory to conventional deoxycholate amphotericin B (AmpB) and 5-flucytosine therapy is reported. He experienced severe AmpB-related side-effects, and was subsequently successfully treated with a pharmaceutical preparation of AmpB (5.7 g) entrapped in sonicated liposomes, composed of lecithin, cholesterol and stearylamine in a molar ratio of 4:3:1. Three months later, during maintenance chemotherapy, liposomal AmpB (5.1 g) was reinstituted due to the finding of biopsies positive for Candida albicans at bronchoscopy. After healing of the patient's fungal infection a left upper lobe resection was performed, which showed advanced fibrosis with signs of inflammation, but no evidence of fungal disease. Since no acute side-effects and only moderate hypokalaemia were observed, it appears that liposomal AmpB is superior to conventional AmpB treatment in granulocytopenic patients with hepatosplenic candidiasis and unbearable therapy-related side-effects.
Björkholm
M
M
Department of Medicine, Karolinska Hospital, Stockholm, Sweden.
Kållberg
N
N
Grimfors
G
G
Eklund
L H
LH
Eksborg
S
S
Juneskans
O T
OT
Udén
A M
AM
D000208:Acute Disease; D000328:Adult; D000666:Amphotericin B / Q000008:administration & dosage*; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy*; D004337:Drug Carriers; D006801:Humans; D007938:Leukemia / Q000150:complications*; D008081:Liposomes; D008107:Liver Diseases / Q000150:complications / Q000188:drug therapy*; D008297:Male; D009894:Opportunistic Infections / Q000188:drug therapy; D013158:Splenic Diseases / Q000150:complications / Q000188:drug therapy*
D004337:Drug Carriers; D008081:Liposomes; D000666:Amphotericin B